^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Biliary Tract Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Biliary Tract Cancers: Useful in Certain Circumstances...Pembrolizumab + lenvatinib (category 2B)